The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-12 2024 | The interaction between bone marrow stromal cells and tumor cells as a potential target in WM
Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the interaction between bone marrow stromal cells and tumor cells in the progression of Waldenström’s macroglobulinemia (WM). Drawing lessons from multiple myeloma, Dr Munshi mentions that this interaction may drive the disease, making it a potential therapeutic target. This interview took place at the 12th International Workshop on Waldenström’s Macroglobulinemia (IWWM-12) in Prague, Czech Republic.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
AbbVie, Adaptive, Amgen, BMS, GSK, J&J, Legend, Novartis, OncoPep, Pfizer, Takeda, Sebia, Recordati.
